Shaping a new era of global health investment, policy, planning and prevention
AVAC Meeting in NYC
Advocacy and activism have been a linchpin in the history of HIV treatment and prevention. The visionary work of passionate advocates has resulted in hard-fought global gains against HIV.
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
Where funders, policies and programs come together.
At the point of service delivery, where options from the pipeline must become choices in people’s lives.
At Parliaments, State Houses, Ministries of Health, National legislatures, and international bodies,to press for global and country accountability.
In the hands of robust and sophisticated coalitions of African-led civil society organizations.
Impact of US Funding Cuts on Services for Key Populations
Percentage of key population-serving implementing partners that have reported full or partial termination of the provision of KP services due to US funding cuts (as of April 2025).
Join us Wednesday, May 20 for Inside the Decisions that Changed Global Health: An AVAC Conversation with Nicholas Enrich, author of Into the Wood Chipper and former global health lead at USAID. Enrich will share an inside perspective on the decisions that led to the dismantling of USAID and the foreign aid freeze and what they mean for global health today.
Official characterizations of the HIV response as “doing very good” warrant a closer look at the data. AVAC’s analysis of PEPFAR prevention figures shows PrEP initiations declined 41% in one year, with women and men each seeing drops exceeding 50%. Data on key populations remains unavailable.
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.